Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Results of NOPHO ALL2008 treatment for patients aged 1-45 years with acute lymphoblastic leukemia

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Toft, N, Birgens, H, Abrahamsson, J, Griškevičius, L, Hallböök, H, Heyman, M, Klausen, TW, Jónsson, ÓG, Palk, K, Pruunsild, K, Quist-Paulsen, P, Vaitkeviciene, G, Vettenranta, K, Åsberg, A, Frandsen, TL, Marquart, HV, Madsen, HO, Norén-Nyström, U & Schmiegelow, K 2018, 'Results of NOPHO ALL2008 treatment for patients aged 1-45 years with acute lymphoblastic leukemia' Leukemia, vol. 32, pp. 606-15. https://doi.org/10.1038/leu.2017.265

APA

CBE

Toft N, Birgens H, Abrahamsson J, Griškevičius L, Hallböök H, Heyman M, Klausen TW, Jónsson ÓG, Palk K, Pruunsild K, Quist-Paulsen P, Vaitkeviciene G, Vettenranta K, Åsberg A, Frandsen TL, Marquart HV, Madsen HO, Norén-Nyström U, Schmiegelow K. 2018. Results of NOPHO ALL2008 treatment for patients aged 1-45 years with acute lymphoblastic leukemia. Leukemia. 32:606-15. https://doi.org/10.1038/leu.2017.265

MLA

Vancouver

Author

Toft, N ; Birgens, H ; Abrahamsson, J ; Griškevičius, L ; Hallböök, H ; Heyman, M ; Klausen, T W ; Jónsson, Ó G ; Palk, K ; Pruunsild, K ; Quist-Paulsen, P ; Vaitkeviciene, G ; Vettenranta, K ; Åsberg, A ; Frandsen, T L ; Marquart, H V ; Madsen, H O ; Norén-Nyström, U ; Schmiegelow, K. / Results of NOPHO ALL2008 treatment for patients aged 1-45 years with acute lymphoblastic leukemia. In: Leukemia. 2018 ; Vol. 32. pp. 606-15.

Bibtex

@article{13e44c8a2c764b858a158f28965d9a10,
title = "Results of NOPHO ALL2008 treatment for patients aged 1-45 years with acute lymphoblastic leukemia",
abstract = "Adults with acute lymphoblastic leukemia (ALL) do worse than children. From 7/2008 to 12/2014, Nordic and Baltic centers treated 1509 consecutive patients aged 1-45 years with Philadelphia chromosome-negative ALL according to the NOPHO ALL2008 without cranial irradiation. Overall, 1022 patients were of age 1-9 years (A), 266 were 10-17 years (B) and 221 were 18-45 years (C). Sixteen patients (three adults) died during induction. All others achieved remission after induction or 1-3 intensive blocks. Subsequently, 45 patients (12 adults) died, 122 patients relapsed (32 adults) with a median time to relapse of 1.6 years and 13 (no adult) developed a second malignancy. Median follow-up time was 4.6 years. Among the three age groups, older patients more often had higher risk ALL due to T-ALL (32{\%}/25{\%}/9{\%}, P<0.001), KMT2A rearrangements (6{\%}/5{\%}/3{\%}, P<0.001) and higher day 29 residual leukemia for B-lineage (P<0.001), but not T-ALL (P=0.53). Event-free survival rates (pEFS5y) were 89±1{\%} (A), 80±3{\%} (B) and 74±4{\%} (C) with significant differences only for non-high risk groups. Except for thrombosis, pancreatitis and osteonecrosis, the risk of 19 specified toxicities was not enhanced by age above 10 years. In conclusion, a pediatric-based protocol is tolerable and effective for young adults, despite their increased frequency of higher risk features.Leukemia advance online publication, 22 September 2017; doi:10.1038/leu.2017.265.",
keywords = "Journal Article",
author = "N Toft and H Birgens and J Abrahamsson and L Griškevičius and H Hallb{\"o}{\"o}k and M Heyman and Klausen, {T W} and J{\'o}nsson, {{\'O} G} and K Palk and K Pruunsild and P Quist-Paulsen and G Vaitkeviciene and K Vettenranta and A {\AA}sberg and Frandsen, {T L} and Marquart, {H V} and Madsen, {H O} and U Nor{\'e}n-Nystr{\"o}m and K Schmiegelow",
year = "2018",
doi = "10.1038/leu.2017.265",
language = "English",
volume = "32",
pages = "606--15",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",

}

RIS

TY - JOUR

T1 - Results of NOPHO ALL2008 treatment for patients aged 1-45 years with acute lymphoblastic leukemia

AU - Toft, N

AU - Birgens, H

AU - Abrahamsson, J

AU - Griškevičius, L

AU - Hallböök, H

AU - Heyman, M

AU - Klausen, T W

AU - Jónsson, Ó G

AU - Palk, K

AU - Pruunsild, K

AU - Quist-Paulsen, P

AU - Vaitkeviciene, G

AU - Vettenranta, K

AU - Åsberg, A

AU - Frandsen, T L

AU - Marquart, H V

AU - Madsen, H O

AU - Norén-Nyström, U

AU - Schmiegelow, K

PY - 2018

Y1 - 2018

N2 - Adults with acute lymphoblastic leukemia (ALL) do worse than children. From 7/2008 to 12/2014, Nordic and Baltic centers treated 1509 consecutive patients aged 1-45 years with Philadelphia chromosome-negative ALL according to the NOPHO ALL2008 without cranial irradiation. Overall, 1022 patients were of age 1-9 years (A), 266 were 10-17 years (B) and 221 were 18-45 years (C). Sixteen patients (three adults) died during induction. All others achieved remission after induction or 1-3 intensive blocks. Subsequently, 45 patients (12 adults) died, 122 patients relapsed (32 adults) with a median time to relapse of 1.6 years and 13 (no adult) developed a second malignancy. Median follow-up time was 4.6 years. Among the three age groups, older patients more often had higher risk ALL due to T-ALL (32%/25%/9%, P<0.001), KMT2A rearrangements (6%/5%/3%, P<0.001) and higher day 29 residual leukemia for B-lineage (P<0.001), but not T-ALL (P=0.53). Event-free survival rates (pEFS5y) were 89±1% (A), 80±3% (B) and 74±4% (C) with significant differences only for non-high risk groups. Except for thrombosis, pancreatitis and osteonecrosis, the risk of 19 specified toxicities was not enhanced by age above 10 years. In conclusion, a pediatric-based protocol is tolerable and effective for young adults, despite their increased frequency of higher risk features.Leukemia advance online publication, 22 September 2017; doi:10.1038/leu.2017.265.

AB - Adults with acute lymphoblastic leukemia (ALL) do worse than children. From 7/2008 to 12/2014, Nordic and Baltic centers treated 1509 consecutive patients aged 1-45 years with Philadelphia chromosome-negative ALL according to the NOPHO ALL2008 without cranial irradiation. Overall, 1022 patients were of age 1-9 years (A), 266 were 10-17 years (B) and 221 were 18-45 years (C). Sixteen patients (three adults) died during induction. All others achieved remission after induction or 1-3 intensive blocks. Subsequently, 45 patients (12 adults) died, 122 patients relapsed (32 adults) with a median time to relapse of 1.6 years and 13 (no adult) developed a second malignancy. Median follow-up time was 4.6 years. Among the three age groups, older patients more often had higher risk ALL due to T-ALL (32%/25%/9%, P<0.001), KMT2A rearrangements (6%/5%/3%, P<0.001) and higher day 29 residual leukemia for B-lineage (P<0.001), but not T-ALL (P=0.53). Event-free survival rates (pEFS5y) were 89±1% (A), 80±3% (B) and 74±4% (C) with significant differences only for non-high risk groups. Except for thrombosis, pancreatitis and osteonecrosis, the risk of 19 specified toxicities was not enhanced by age above 10 years. In conclusion, a pediatric-based protocol is tolerable and effective for young adults, despite their increased frequency of higher risk features.Leukemia advance online publication, 22 September 2017; doi:10.1038/leu.2017.265.

KW - Journal Article

U2 - 10.1038/leu.2017.265

DO - 10.1038/leu.2017.265

M3 - Journal article

VL - 32

SP - 606

EP - 615

JO - Leukemia

JF - Leukemia

SN - 0887-6924

ER -

ID: 52175161